Page 37 - CPG endometrial cancer

32

แนวทางการตรวจคัดกรอง วนิ ิจฉยั และรักษาโรคมะเรง็ เย่อื บุโพรงมดลกู

23. De Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women
with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre,
randomised, phase 3 trial. Lancet Oncol 2018;19:295–309.

24. Randall M, Filiaci V, McMeekin D, et al. A phase 3 trial of pelvic radiation therapy versus vaginal cuff brachytherapy
followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: a
Gynecology Oncology Group study. Int J Radiat Oncol Biol Phys 2017;99:1313.

25. De Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with
highrisk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised
phase 3 trial. Lancet Oncol 2019;20:1273–85.

26. Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial
cancer. N Engl J Med. 2019;380(24):2317-2326.

27. Goodman CR, Hatoum S, Seagle BL, Donnelly ED, Barber EL, Shahabi S, Matei DE, Strauss JB . Association of
chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer .
Gynecol Oncol. 2019 Apr;153(1):41-48.

28. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in
advanced endometrial cancer. N Engl J Med 2023;388(23):2159-2170.

29. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov?k Z, Black D, et al. Dostarlimab for primary advanced
or recurrent endometrial cancer. N Engl J Med 2023;388(23):2145-2158.

30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasm
Version 2.2023. 2023 Apr 28. [internet]. Available from:https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
Accessed on September 23, 2023

31. Pignata S, Marth C, Moore RG, Bidzinski M, Ayhan A, Rubio P?rez MJ, et al. Phase III ENGOT- En9/ LEAP- 001 study:
Lenvatinib +pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or
recurrent endometrial cancer. Abstract#39MO. ESMO Open (Abstract) 2024; 9. https://doi.org/10.1016/j.esmoop.2024.103539.